• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Percentage of regulatory cases referred to OFS that were reviewed within the timeframe given to OFS in the Case Management System (measures time in OFS only) in the month

Dictionary: Timely review of regulatory cases that come from the field is important as it allows FDA to take appropriate regulatory action such as issuance of a warning letter to the regulated industry. This can lead to a timely correction of problems in the industry resulting in a safer food supply.

Information is current as of June 30, 2014.

Fiscal Year - 2010

Skip graphic and jump to text data

TimeTargetPercentage
Oct 2009TBDN/A
Nov 2009TBDN/A
Dec 2009TBDN/A
Jan 2010TBDN/A
Feb 2010TBDN/A
Mar 2010TBDN/A
Apr 2010TBDN/A
May 2010TBD67
Jun 2010TBD72
Jul 2010TBD76
Aug 2010TBD62
Sep 2010TBD70

FY 2010 5 Month Overall: 69%

Total number of regulatory cases referred to OFS that were reviewed within the timeframe given to OFS in the Case Management System (measures time in OFS only) in the month

Fiscal Year - 2010
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2009N/AN/A
Nov 2009N/AN/A
Dec 2009N/AN/A
Jan 2010N/AN/A
Feb 2010N/AN/A
Mar 2010N/AN/A
Apr 2010N/AN/A
May 2010N/A18
Jun 2010N/A13
Jul 2010N/A19
Aug 2010N/A13
Sep 2010N/A23

FY 2010 5 Month Total: 86

Total number of regulatory cases referred to OFS in the month that are due within the month

Fiscal Year - 2010
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2009N/AN/A
Nov 2009N/AN/A
Dec 2009N/AN/A
Jan 2010N/AN/A
Feb 2010N/AN/A
Mar 2010N/AN/A
Apr 2010N/AN/A
May 2010N/A27
Jun 2010N/A18
Jul 2010N/A25
Aug 2010N/A21
Sep 2010N/A33

FY 2010 5 Month Total: 124

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.